Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT04343235 · ClinicalTrials.gov registry record · Phase 4
Postpartum Management of Gestational Hypertensive Disorders Using Furosemide
A Phase 4 study, sponsored by Wright State University.
- Terminated
- Registry status
- Phase 4
- Development phase
- 13
- Enrollment target
NCT04343235 is a Phase 4 study that was terminated before completion, run by Wright State University. The registered enrollment target is 13 participants.
The verdict
NCT04343235, a Phase 4 study, was terminated before completion, sponsored by Wright State University.
- TERMINATED
- Registry status
- Phase 4
- Development phase
- 13 participants
- Enrollment target
Study Summary
* The main purpose of this study is to learn if incorporating a loop diuretic such as furosemide along with labetalol in the routine management of postpartum gestational hypertensive disorders could lower the need for additional anti-hypertensive agents to control blood pressures, improve blood pressures (as measured by systolic blood pressure, diastolic blood pressure and mean arterial blood pressures), shorten hospital stays and decrease readmissions for patients with gestational hypertensive disorders. * Based on a study by Veena et al1, there is reason to believe that the addition of furosemide to other anti-hypertensives may help decrease the need to add or increase the dose of medication to control blood pressures. There may be potential to shorten hospital stays and decrease readmissions, as well. Collecting data will be done using a prospective, randomized 1:1 controlled study assigning postpartum patients with a gestational hypertensive diagnosis to either labetalol alone or labetalol plus furosemide. * The study will be performed in the postpartum wing of Miami Valley Hospital Main Campus and would use patients who have consented to participate in the study with enrollees coming from the OB Staff population.
Interventions
- DRUG labetalol
- DRUG furosemide
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 13 participants |
| Start Date | 2020-05-01 |
| Est. Completion | 2022-06-30 |
| Phase | Phase 4 |
Interested in This Trial?
Full Details on ClinicalTrials.gov ↗What the Registry Record Tells You About NCT04343235
The ClinicalTrials.gov registry entry for NCT04343235 describes a study currently listed as terminated, categorized as Phase 4. The registered enrollment target is 13 participants, a figure that helps gauge the scale of data the investigators plan to collect. The listed sponsor is Wright State University, which has 32 total studies on file at ClinicalTrials.gov.
The record links to 0 conditions, and to 2 interventions - of which labetalol is the first listed.
NCT04343235 reports 0 study locations.
Frequently Asked Questions
What is clinical trial NCT04343235 about?
NCT04343235 is a clinical study titled "Postpartum Management of Gestational Hypertensive Disorders Using Furosemide". * The main purpose of this study is to learn if incorporating a loop diuretic such as furosemide along with labetalol in the routine management of postpartum gestational hypertensive disorders could lower the need for additional anti-hypertensive agents to control blood pressures, improve blood pres...
What is the current status of trial NCT04343235?
This trial is currently terminated. It is a Phase 4 study. The enrollment target is 13 participants. The study started on 2020-05-01. Estimated completion is 2022-06-30.
What interventions are being tested in trial NCT04343235?
The interventions under investigation include: labetalol (DRUG), furosemide (DRUG).
Who is sponsoring clinical trial NCT04343235?
This trial is sponsored by Wright State University, which has 32 total clinical trials registered on ClinicalTrials.gov.
Learn More About Clinical Trials
Explore more on PlainTrial
Read our methodology - how this data is sourced, computed, and verified.
Related
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.